- Company
- Dong-A ST, exports ₩3 billion in the first half
- by Kim, Jin-Gu Aug 27, 2020 06:24am
- Dong-A ST's Nesp biosimilar is targeting the Japanese market. After launching the product in the Japanese market at the end of last year, it made exports for the first time in the first half of this year. Chong Kun Dang is also targeting the Japanese market in earnest after launching Nesp biosimilar in the Japanese market around the same time
- Company
- Keytruda sales hit KRW 72.3 bln topping H1 2020
- by Chon, Seung-Hyun Aug 27, 2020 06:24am
- Apparently an immunotherapy Keytruda has made the highest sales revenue in the first half of the year. Keytruda has beaten the long-term industry leader, Lipitor. Two innovative new drugs from multinational pharmaceutical companies, Tagrisso and Spinraza have shown outstanding performances, and the sharp surge in pneumococcal pneumonia vaccine P
- Company
- Statin+Ezetimibe reduces the burden of high doses Statin
- by Aug 27, 2020 06:23am
- The 'Statin + Ezetimibe' combination drug is shaking the market for hyperlipidemia treatment. In 2015, the 'IMPROVE-IT' study, which proved the low-density lipoprotein cholesterol (LDL-C) lowering effect of the combination therapy of Ezetimibe(non-statin) and Statins, targets a niche market that is concerned about side effects of high-dose St
- Company
- Initiating talks on listing EBC adjuvant therapy Kadcyla
- by Eo, Yun-Ho Aug 26, 2020 06:24am
- The talks on granting healthcare reimbursement on Kadcyla as an adjuvant therapy following an early breast cancer surgery would begin. Today, South Korea’s Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee would deliberate providing the healthcare reimbursement on an antibody-drug conjugate (ADC) Kadcyl
- Company
- “Access to Onivyde should improve for more options"
- by Aug 26, 2020 06:23am
- “Besides the findings from global clinical study on treating metastatic pancreatic cancer patients, Onivyde even offers subset analysis on Asian patients and real-world evidence (RWE) in South Korea. It is regretful the treatment has not been listed for National Health Insurance (NHI) reimbursement.” On Aug. 20, Professor Yoo Chang-hoo
- Company
- ↓generic's approval as the drug price system is implemented
- by Chon, Seung-Hyun Aug 26, 2020 06:22am
- The number of approval for generic drugs has declined for the second consecutive month. If the bioequivalence test is not performed, the new drug price system, which gives low drug prices, was implemented, and greatly reduced the number of new licenses for authorized generics. Some point out that the government's move to strengthen generic regul
- Company
- There is still misinformation and choice regarding MPHL
- by Eo, Yun-Ho Aug 25, 2020 06:14am
- The male-type hair loss treatment'Propecia (finasteride 1mg)' was introduced in Korea, and hair loss was treated in earnest in 2000. Propecia identified the correlation between type II 5-alpha reductase and male pattern hair loss, suggested the therapeutic potential of male pattern hair loss, which was considered an incurable hereditary d
- Company
- Celltrion begins to develop oral Remsima following SC type
- by Kim, Jin-Gu Aug 24, 2020 06:19am
- Celltrion starts developing oral 'Remsima'. Celltrion announced on the 20th that it has signed a joint research agreement with British biotechnology company Intract Pharma. Remicade, Remsima's original drug, is a drug administered by intravenous injection.. Celltrion has already developed and commercialized Remsima SC, the first in the wor
- Company
- United promotes phase III tx for COVID-19 in the Philippines
- by Aug 24, 2020 06:18am
- Korea United Pharmaceutical (CEO Kang Deok-young) is starting to develop a cure for COVID-19. It is Drug Repositioning of the company's Incrementally Modified Drug 'UI030'. United said on the 19th, "UI030 has confirmed the antiviral effect of up to 30 times compared to Ciclesonide in cell experiments." According to the company, UI030 is
- Company
- Patent dispute for Promac, eventually to Supreme Court
- by Kim, Jin-Gu Aug 24, 2020 06:18am
- The patent dispute over the anti-ulcer drug, Promac (Polaprezinc) was finally concluded in the Supreme Court. According to the pharmaceutical industry on the 19th, SK Chemical, which holds a formulation patent for Promac, recently filed an appeal to the Supreme Court against Hana Pharm and Korea Prime. Earlier, on the 17th of last month
